Impact Therapeutics, a biopharmaceutical company, has reportedly announced the completion of its Series D1 financing.

Dingxin Capital, C&D EMERGING CAPITAL, CCBT, Sam Isaly-led Exome Asset Management are some of the new investors that took part in this round along with current shareholders China Summit, LAV (Lilly Asia Ventures), and Yuexiu.

The funds will be utilized to expedite the development of its synthetic lethality programs, several of which are showcasing top potential.

Last year, Impact Therapeutics attained milestones across several targets including Wee1, PARP, and ATR, becoming one of the biotech firms with the world’s broadest DDR (DNA damage response) pipelines and is broadening to other advanced synthetic lethality targets to widen its pipelines. The company already has three synthetic lethality compounds currently in the clinical stage.

According to the Chief Executive Officer and President of Impact Therapeutics Dr. Jun Bao, the successful closure of this transaction gave the company more confidence to execute its strategy of global development and rapidly advance different clinical trials.

For the record, Impact Therapeutics is committed to discovering and developing synthetic lethality-based targeted anti-cancer therapeutics. The company has mustered one of the most complete DDR global pipelines of advanced drug candidates produced by in-house discovery efforts and is broadening to other advanced synthetic lethality targets to expand its pipeline.

Some of the products of the Impact pipeline include Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064), PARP inhibitor (Senaparib/ IMP4297), and other advanced DDR pathway inhibitors. PARP inhibitor (Senaparib/ IMP4297), the lead clinical program, is currently in Phase II/III studies for small cell lung cancer, prostate cancer, ovarian cancer, and other indications globally including China.

The preliminary clinical data of Senaparib exhibited superior tolerability and broader therapeutic windows in comparison to other PARPi. Wee1 inhibitor (IMP7068)’s Phase I study is performed worldwide. FDA has provided IND Clearance to ATR Inhibitor IMP9064 to initiate clinical studies in the United States and provided clinical application in China.

Source credit:

https://www.prnewswire.com/news-releases/impact-therapeutics-announces-completion-of-series-d1-financing-301501583.html